Can I get a p-tau217 blood test through my GP now?

No. This test is not currently available through Australian general practice or pathology services. The research was presented at a scientific conference and the test is being used in research settings to identify people for clinical prevention trials, not for routine clinical assessment. Diagnostic biomarker tests for dementia risk in asymptomatic individuals face a different regulatory and clinical pathway from tests used in people who already have symptoms, and that pathway takes years.

If a test like this became available, what would it actually mean for me?

Knowing you have elevated biological markers for Alzheimer's before you have symptoms would only be useful if there were something effective to do with that information — a drug, an intervention, a changed management plan. At this point, there is no approved pharmacological prevention for Alzheimer's in people without symptoms. The researchers' intent is to use the test to identify people for prevention drug trials, not to generate individual-level clinical decisions. The actions that current evidence supports for brain health — cardiovascular risk management, exercise, sleep, and staying cognitively and socially active — are the same whether or not you'd test positive.

A blood test could flag Alzheimer's risk a decade before symptoms appear

Note: this evidence comes from international research (US population, presented at a US-led conference). There are no Australian-specific clinical data on the p-tau217 test. Flagged as international fallback — AU primary literature is silent on this question at time of writing.

What just happened

Research presented at the Alzheimer’s Association International Conference 2026 in London has added weight to one of the most actively investigated questions in dementia medicine: can a simple blood test identify people at elevated risk for Alzheimer’s years before any symptoms appear?

The study tracked 2,684 healthy older adults enrolled since 2004 — people without any cognitive symptoms at entry — and measured levels of a blood protein called phosphorylated tau-217 (p-tau217) at baseline. Over follow-up, 478 participants developed cognitive impairment. The relationship between baseline p-tau217 levels and who went on to develop impairment was striking: those with high baseline levels faced a 38% risk of cognitive impairment within five years and a 78% risk within ten. Those with low levels had risk trajectories that matched typical ageing.

The lead researcher, Professor Reisa Sperling from Mass General Brigham’s Neuroscience Institute, described the potential clearly: the test could identify people for prevention trials before they have symptoms, rather than waiting for the clinical presentation that currently defines who gets enrolled.

Both-and

Why this is genuinely significant

The existing landscape of Alzheimer’s diagnostics is largely reactive: lumbar puncture for cerebrospinal fluid biomarkers, or PET scans for amyloid and tau deposits in the brain — both invasive or expensive, both typically ordered in people who already have symptoms or established cognitive impairment. A blood-based biomarker that works years before symptoms would change the timing of intervention entirely.

The 10-year predictive window is what makes this signal different from earlier work in this field. P-tau217 levels in blood appear to reflect underlying tau pathology accumulating in the brain — the same biology being targeted by newer disease-modifying Alzheimer’s drugs approved in the US and under review in Australia. If those drugs work better when given earlier (before neuronal damage accumulates), a test that identifies people early enough to intervene has obvious therapeutic logic.

For a 45-year-old woman whose parent or grandparent had Alzheimer’s, the concept of knowing her biological risk a decade ahead — and potentially joining a prevention trial — is not abstract. It is exactly the kind of information the system does not currently provide, and that many patients quietly wonder about at every GP visit where the topic of dementia comes up.

Why the “maybe” verdict holds

This research was presented at a conference, not published in a peer-reviewed journal yet. The study population was entirely US-based — healthy older adults enrolled at academic research centres in the United States. There are no Australian-specific data.

The more substantive concern is downstream: even with an accurate predictive blood test, knowing you are at elevated risk for Alzheimer’s in the research context is not the same as having a clinically actionable result. Professor Jessica Langbaum from the Banner Alzheimer’s Institute called the finding a “game changer” for identifying prevention trial candidates — not for individual clinical decision-making. That distinction matters.

There is currently no approved pharmacological intervention that prevents Alzheimer’s in people without symptoms. There are lifestyle interventions with meaningful evidence — exercise, sleep, cardiovascular risk management — but those recommendations are the same regardless of p-tau217 status. A positive test result, without an effective action to take in response to it, generates anxiety rather than agency.

The test may eventually make it into clinical practice as prevention drug trials mature. We are not there yet.

My two cents

The question this research is really asking is not “can we detect Alzheimer’s early?” — it’s “early enough to do something about it?” Those are different questions, and the second one depends on where the drug pipeline lands.

The most honest framing of this research for anyone who reads about it is: there is a blood marker that predicts future risk with meaningful accuracy in a research population, it is being developed specifically to power prevention trials, and the preventive interventions those trials will test are not yet proven. We are watching the pipeline build, not reporting a clinical tool that is available to use.

What has not changed is the evidence base for the actions that currently reduce dementia risk: regular aerobic exercise, adequate sleep, managing blood pressure and cholesterol, not smoking, and staying cognitively and socially engaged. A future blood test will not substitute for any of those. For now, they are both the recommendation and the only actionable response to whatever a future biomarker test would show.

Verdict: maybe — promising international research on a predictive biomarker, not yet published or clinically available; no Australian data. Current brain-health recommendations unchanged.

Sources cited

Could Alzheimer’s be predicted years before symptoms? A test offers new clues. SBS News, 19 July 2026. https://www.sbs.com.au/news/article/could-alzheimers-be-predicted-years-before-symptoms-a-test-offers-new-clues/ae6djp3hy
Alzheimer’s Association International Conference 2026. https://aaic.alz.org